A share price of Brainstorm Cell Therapeutics, Inc. [BCLI] is currently trading at $0.31, down -4.36%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The BCLI shares have gain 10.99% over the last week, with a monthly amount drifted -24.50%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Brainstorm Cell Therapeutics, Inc. [NASDAQ: BCLI] stock has seen the most recent analyst activity on February 04, 2021, when Maxim Group upgraded its rating to a Buy but kept the price target unchanged to $12 for it. Previously, Maxim Group downgraded its rating to Hold on November 17, 2020. On December 19, 2016, Maxim Group reiterated its Buy rating and revised its price target to $6 on the stock. Maxim Group reiterated its Buy rating and decreased its price target to $5 on December 22, 2015.
Brainstorm Cell Therapeutics, Inc. experienced fluctuations in its stock price throughout the past year between $0.13 and $1.81. Brainstorm Cell Therapeutics, Inc. [NASDAQ: BCLI] shares were valued at $0.31 at the most recent close of the market.
Analyzing the BCLI fundamentals
Gross Profit Margin for this corporation currently stands at -0.4% with Operating Profit Margin at -114.06%, Pretax Profit Margin comes in at -91.7%, and Net Profit Margin reading is -91.7%. To continue investigating profitability, this company’s Return on Assets is posted at -6.83, Equity is 2.51 and Total Capital is 2.72. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of-0.13.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.2933 points at the first support level, and at 0.2815 for the second support level. However, for the 1st resistance point, the stock is sitting at 0.3227, and for the 2nd resistance point, it is at 0.3403.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Brainstorm Cell Therapeutics, Inc. [NASDAQ:BCLI] is 0.18. Further, the Quick Ratio stands at 0.18, while the Cash Ratio is 0.45.
Transactions by insiders
Recent insider trading involved Dagher Ibrahim B., Chief Medical Officer, that happened on Jul 19 ’24 when 63000.0 shares were sold. Co-Chief Executive Officer, Lindborg Stacy completed a deal on Sep 01 ’23 to buy 11500.0 shares.
